Targeting inflammation in endometriosis: emerging therapeutic options.
Endometriosis is a chronic, estrogen-dependent inflammatory disease affecting up to 10% of reproductive-aged women. Current therapies are predominantly hormone-based and offer symptomatic relief without correcting the immune dysregulation and inflammation …
Endometriosis as an immune-mediated disease: pathogenetic mechanisms and therapeutic strategies.
Endometriosis, which affects approximately 10% of women of reproductive age, is a complex inflammatory disease with significant immune system disturbances caused by an inadequate immune response to retrograde menstruation and …
Ovarian squamous cell carcinoma: clinicopathological features, prognosis and immunotherapy outcomes.
To explore the characteristics and survival outcomes of ovarian squamous cell carcinoma (SCC) and the treatment effectiveness of immune checkpoint inhibitors (ICIs).
The immunotherapy era in ovarian clear cell carcinoma: current evidence and future perspective.
Ovarian clear cell carcinoma (OCCC) is a rare, aggressive epithelial ovarian cancer subtype, accounting for approximately 10% of cases and associated with a poor prognosis due to chemoresistance and unique …
Correction: Receptor tyrosine kinase inhibitor sunitinib as novel immunotherapy to inhibit myeloid-derived suppressor cells for treatment of endometriosis.
[This corrects the article DOI: 10.3389/fimmu.2021.641206.].